SEC Form 4 · accession 0001209191-16-152812

Aimmune Therapeutics, Inc. · AIMT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Table I — non-derivative securities

Table II — derivative securities

Explanation of responses

• F1Represents a pro rata distribution from Longitude Venture Partners II, L.P. ("Longitude Venture II") to its partners for no consideration. Longitude Capital Partners II, LLC ("Longitude Capital II"), the sole general partner of Longitude Venture II, received a pro rata allocation of the distributed shares in accordance with its ownership, and further distributed its allocation to its managing members.
• F2This report is filed jointly by Longitude Capital II, Longitude Venture II, and Juliet Tammenoms Bakker, a managing member of Longitude Capital II, with respect to the securities held and transactions effected by Longitude Venture II. Patrick G. Enright, a managing member of Longitude Capital II, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital II and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interest therein.
• F3Following the pro rata distribution described in Footnote 1, these shares became directly beneficially owned by Ms. Bakker. Neither Longitude Capital II nor Longitude Venture II has voting, investment or dispositive power over any of the shares directly held by Ms. Bakker and disclaim beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that Longitude Capital II and Longitude Venture II are the beneficial owners of these shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.